COMy 2019 | Proteasome inhibitors-based combinations for elderly MM
Maria-Victoria Mateos
• 17 May 2019
María-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses the improvement in proteasome inhibitor-based combinations brought about for the management of newly diagnosed multiple myeloma (MM) in elderly patients. First used with a backbone of melphalan/prednisone, Dr Mateos says that various combinations are being used across the globe to treat this population of patients. Additionally, monoclonal antibodies, for example daratumumab, can be used on top of proteasome inhibitor-based combination of bortezomib, melphalan, prednisone (VMP). This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.
